This is a single-arm, exploratory clinical study.
Gender: no restriction; Age: 18-75 years.
Histologically or cytologically confirmed diagnosis of esophageal squamous cell carcinoma.
Clinical stage II-IVa (T2-4aN+M0) according to the AJCC 8th edition, and assessed as resectable by a multidisciplinary team (MDT).
Neck ultrasound and contrast-enhanced chest/abdominal CT.
Known history of hypersensitivity to macromolecular protein preparations. Contraindications or allergies to any component of epaplimut-pembrolizumab.
Other anti-tumor therapies (chemotherapy, radiotherapy, surgery, immunotherapy, biological therapy, chemoembolization, anti-tumor traditional Chinese herbal medicine).
Radiographic diagnosis indicating distant metastasis of the tumor.
History of allogeneic tissue/solid organ transplantation.